Recent Advances in Pharmacologic Treatments of Drug-Resistant Epilepsy: Breakthrough in Sight.
- Published in:
- CNS Drugs, 2024, v. 38, n. 12, p. 949, doi. 10.1007/s40263-024-01130-y
- By:
- Publication type:
- Article
Works matching IS 11727047 AND DT 2024 AND VI 38 AND IP 12
Results: 7
1
2
Acknowledgement to Referees.
- Published in:
- CNS Drugs, 2024, v. 38, n. 12, p. 943, doi. 10.1007/s40263-024-01129-5
- Publication type:
- Article
3
Efficacy of Cariprazine in the Psychosis Spectrum: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials in Schizophrenia and Bipolar Disorder.
- Published in:
- CNS Drugs, 2024, v. 38, n. 12, p. 961, doi. 10.1007/s40263-024-01125-9
- By:
- Publication type:
- Article
4
A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder.
- Published in:
- CNS Drugs, 2024, v. 38, n. 12, p. 1003, doi. 10.1007/s40263-024-01124-w
- By:
- Publication type:
- Article
5
Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder.
- Published in:
- CNS Drugs, 2024, v. 38, n. 12, p. 985, doi. 10.1007/s40263-024-01123-x
- By:
- Publication type:
- Article
6
Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study.
- Published in:
- CNS Drugs, 2024, v. 38, n. 12, p. 1017, doi. 10.1007/s40263-024-01118-8
- By:
- Publication type:
- Article
7
Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis.
- Published in:
- CNS Drugs, 2024, v. 38, n. 12, p. 973, doi. 10.1007/s40263-024-01117-9
- By:
- Publication type:
- Article